New Chapter for Gene Therapy in Inherited Retinal Diseases: Syncona Acquires AGTC
For individuals and families affected by inherited retinal diseases (IRDs), news in the gene therapy space offers a constant source of hope and anticipation. A significant development occurred in late 2022 when Syncona, a healthcare investment firm, acquired Applied Genetic Technologies Corporation (AGTC), a biotechnology company focused on gene therapies for rare and debilitating ophthalmic diseases. This acquisition, valued at $23.5 million upfront, aims to ensure the continued advancement of promising gene therapy candidates despite a challenging funding environment for biotech companies.
AGTC's pipeline has been dedicated to inherited retinal diseases, with its most advanced program, AGTC-501, targeting X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene. This candidate was in a Phase 2 expansion study at the time of the acquisition. XLRP is a severe, early-onset form of IRD that primarily affects males, leading to progressive vision loss. AGTC also had Phase 1/2 programs for achromatopsia and an optogenetics approach for retinal degeneration.
The acquisition by Syncona, which was completed by December 1, 2022, means that AGTC became an indirect, wholly-owned subsidiary of Syncona. This move was seen as crucial for AGTC to continue its operations beyond 2022, given the difficulties in securing funding in the broader market. Syncona has prior experience in the eye gene therapy sector, having been involved with other gene therapy developers in the past.
For patients and families navigating the complexities of IRDs, this acquisition underscores the ongoing commitment to developing new treatments. The continued progression of AGTC-501 for XLRP, under Syncona's stewardship, is particularly meaningful as XLRP has been a significant target for gene therapy developers. The transition aims to advance this therapy towards patients, ensuring that the research and development efforts can persist. While the funding landscape can be unpredictable, the focus remains on bringing potential vision-saving therapies closer to those who need them.
This development highlights the dynamic nature of biotech funding and its direct impact on the pace of therapeutic innovation for rare diseases. The goal is to ensure that promising research, particularly in gene therapy, can overcome financial hurdles to reach clinical development and, ultimately, patients.